54621-18-0 Usage
Description
1-Amino-4-oxocyclohexanecarboxylic acid ethylene ketal is an organic compound that features a cyclohexane ring with an amino group, a carbonyl group, and an ethylene ketal moiety. This unique structure endows it with versatile chemical properties, making it a valuable component in various applications.
Uses
Used in Polymer Modification:
1-Amino-4-oxocyclohexanecarboxylic acid ethylene ketal is used as a modifying agent for polymer properties. Its incorporation into polymers can enhance their characteristics, such as improving mechanical strength, thermal stability, and chemical resistance. This modification can lead to the development of advanced materials with tailored properties for specific applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 54621-18-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,6,2 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 54621-18:
(7*5)+(6*4)+(5*6)+(4*2)+(3*1)+(2*1)+(1*8)=110
110 % 10 = 0
So 54621-18-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H15NO4/c10-8(7(11)12)1-3-9(4-2-8)13-5-6-14-9/h1-6,10H2,(H,11,12)
54621-18-0Relevant articles and documents
PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS
-
Paragraph 0341-0342, (2021/02/05)
The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention.
PEPTIDYL NITRILCOMPOUNDS AS PEPTIDASE INHIBITORS
-
Page/Page column 109, (2012/09/22)
The invention relates to compounds of Formula (II) and their use in theraphy as peptidase inhibitors.
Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
-
Page 13, (2010/11/30)
This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydro